Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janette Greenhalgh

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics|April 12, 2013
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics - Open|April 16, 2020
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachel Houten, Janette Greenhalgh, James Mahon, et al.
Pharmacoeconomics|October 18, 2018
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalTosin Lambe, Rui Duarte, James Mahon, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Health Technology Assessment (Winchester, England)|July 3, 2015
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluationJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluationRui Duarte, Angela Stainthorpe, Janette Greenhalgh, et al.
Plos One|December 24, 2019
Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluationRui Duarte, Angela Stainthorpe, James Mahon, et al.
The Cochrane Database of Systematic Reviews|November 8, 2016
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the childJennifer Weston, Rebecca Bromley, Cerian F Jackson, et al.
Pharmacoeconomics - Open|May 17, 2023
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRebecca Bresnahan, Rachel Houten, Janette Greenhalgh, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics|April 12, 2013
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics - Open|April 16, 2020
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachel Houten, Janette Greenhalgh, James Mahon, et al.
Pharmacoeconomics|October 18, 2018
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalTosin Lambe, Rui Duarte, James Mahon, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Health Technology Assessment (Winchester, England)|July 3, 2015
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluationJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluationRui Duarte, Angela Stainthorpe, Janette Greenhalgh, et al.
Plos One|December 24, 2019
Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluationRui Duarte, Angela Stainthorpe, James Mahon, et al.
The Cochrane Database of Systematic Reviews|November 8, 2016
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the childJennifer Weston, Rebecca Bromley, Cerian F Jackson, et al.
Pharmacoeconomics - Open|May 17, 2023
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRebecca Bresnahan, Rachel Houten, Janette Greenhalgh, et al.
Pageof 4